Characterization, Qualification, and Validation of a Disposable Final Filling Process for Parenteral and Ophthalmic Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Characterization, Qualification, and Validation of a Disposable Final Filling Process for Parenteral and Ophthalmic Drugs


Pharmaceutical Technology


Many articles describe the growing need for and benefits of the replacement of traditional, reusable technologies with disposable, single-use components in the pharmaceutical and biotechnology industries (1–6). Replacing reusable materials (e.g., stainless steel) with disposable products is cost effective and increases operator and product safety (3–6).

For disposable technologies to be accepted by an industry, vendors must show that disposable systems can have equal or better performance than traditional systems. As vendors begin supplying complete sterile, disposable solutions to the pharmaceutical and biotechnology industries, suppliers will be required to have complete validation packages and an in-depth understanding of their products.

The first decision that must be made when designing and manufacturing a disposable assembly is the choice of materials to be used. The materials typically chosen are polymeric materials that must be sterilized using common sterilization methods. Typically, prepackaged, presterilized disposable assemblies are gamma irradiated at >25 kGy. Therefore, the materials of these assemblies must be nontoxic and resist changes to their physical properties after being irradiated.

Once the materials are chosen, bioburden (i.e., the level of contamination) must be minimized during the assembly process. Low levels of bioburden are required throughout the product fluid path to ensure endotoxin levels are well below accepted levels. Overall bioburden levels for inner and outer material surfaces also must be monitored carefully and maintained during the manufacture of the disposable modules to ensure the validity of the subsequent sterilization process.

Validated and guaranteed product sterility is the most critical parameter for disposable systems in final fill and finish. Manufacturers of disposable products that are intended for a Class 100 environment or better must prove sterility throughout the fluid path as well as on the products' outer surfaces.

The validation method must then show that the disposable process is reliable, robust, and safe. The final filling performance of the disposable system must be validated and qualified to show repeatability and robustness. The levels of extractables and particulates for the chosen materials must be quantified, and the major contributing components must be identified. In addition, it must be proven that the final packaged assemblies maintain sterility and integrity during storage.

The final test for any disposable product is to show that it maintains product sterility during actual operating conditions. In the case of final fill and finish, the last step in the process validation is to perform media trials in which the final filling process is interrupted by process interventions while media are dispensed, packaged, and tested for sterility.


Figure 1
The following sections present details and results of the validation of a disposable filling system. All media fills were performed at St. Jude Children's Research Hospital (Memphis, TN). The system validated was the Acerta DS1 dispensing system (Millipore Corporation, Billerica, MA), and its disposable module used to perform the media fill is described. Figure 1 shows the dispensing system with a disposable module installed. The module consists of tubing, connectors, a reservoir, and a needle, all of which are disposable.

Methods, results, and discussion

Biological validation. The choice of materials to use is the first critical step in providing a robust, sterile product. As described in the "Performance validation" section that follows, none of the materials chosen should show significant physical degradation after gamma irradiation. Because the materials used for the disposable assemblies are polymeric, they must conform to safety standards for plastics set forth by the United States, European, and Japanese Pharmacopeias. To ensure this, each material that may come into contact with the drug product must pass United States Pharmacopeia (USP) 27 ‹88› "Biological Reactivity Tests In Vivo" after the samples are gamma irradiated to >40 kGy, the maximum dosage level that the disposable product may experience.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
The Effect of Carrier Material on the Measured Resistance of Spores
A Risk-Based Approach to the Use of Biological Indicators in the Development and Control of Steam-Sterilization Processes
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Understanding Overkill Sterilization: An End to the Confusion
post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here